Advanced Search
Reset

Day 3 (2018-07-02)

14:45
16:15
State-of-the-Art Session: Recurrent Liver Allograft Disease: How to Deal With
N-101
360.1 Acute versus chronic alcoholic liver disease: real incidence and how to prevent recurrence
Christophe Moreno, Belgium
360.2 Recurrent Viral B and C disease: is the graft still salvageable?
Marina Berenguer, Spain
360.3 Recurrent hepatocellular cancer: is there a place for surgery?
Shusen Zheng, P.R. China
14:45
16:15
State-of-the-Art Session: Paediatric Transplantation: Challenges and Potential Solutions
N-102
361.1 Ethics of transplanting the non-adherant teen
Grainne M Walsh, United Kingdom
361.2 Long term outcomes of paediatric transplantation
Carlos O. Esquivel, United States
361.3 Biomarkers for PTLD diagnosis and therapies
Olivia M. Martinez, United States
14:45
16:15
State-of-the-Art Session: Strategies for the Sensitized Patient
N-103
362.1 IdeS: a new approach to desensitization
Robert A. Montgomery, United States
362.2 Anti-IL-6R Ab for the prevention and treatment of AMR
Olivier Aubert, France
362.3 The role of the acceptable mismatch strategy for sensitized patients
Frans HJ Claas, Netherlands
14:45
16:15
State-of-the-Art Session: New Therapeutic Approaches to Transplantation
N-104
363.1 Mechanisms of organ injury and repair by macrophages
Menna R. Clatworthy, United Kingdom
363.2 Systems biology of the intragraft regional immunoregulation in tumor recurrence after liver transplantation
Nancy Kwan Man, Hong Kong
363.3 Nudging clinical Treg responses
Qizhi Tang, United States
14:45
16:15
State-of-the-Art Session: New Strategies to Increase Donation
N-105
364.1 Donor intervention research - priorities and trends
Claus Niemann, United States
364.2 Effective family approach practices
Howard M Nathan, United States
364.3 End of life care decision making impact on donation
Kristina Krmpotic, Canada
14:45
16:15
State-of-the-Art Session: Inflammation and Stem Cell Transplantation
N-106
365.1 Stem cell therapy, hepatocytes, a source for liver regeneration
Anil Dhawan, United Kingdom
365.2 Pursing tolerance by blocking inflammation in islet transplantation
Maria Koulmanda, United States
365.3 Advances in MR cell imaging
Frantisek Saudek, Czech Republic
14:45
16:15
State-of-the-Art Session: Cutting Edge of Allorecognition
N-107/108
366.1 Novel immune allorecognition pathways
Megan Sykes, United States
366.2 MHC:T-Cell receptor allorecognition interface
James McCluskey, Australia
366.3 MHC:B-Cell receptor allorecognition interface
Olivier Thaunat, France
14:45
16:15
State-of-the-Art Session: The Future of of Intestinal Transplantation
N-111
367.1 The microbiome and its implications in ITX
Alexander Kroemer, United States
367.2 Current knowledge on regulation and impairment of motility after intestinal transplantation
Martin W von Websky, Germany
367.3 Alloimmunity of the intestinal allotransplant
Martin Rumbo, Argentina
14:45
16:15
State-of-the-Art Session: Novel Technologies and Tools in VCA
N-115/116
368.1 Nanomedicine Strategies for VCA - Prospects and Potential
Jelena M. Janjic, United States
368.2 Vascularized composite allograft engineering - the new frontier
Benoit Lengele, Belgium
368.3 Cortical integration after VCA-relevance in hand and face transplants
Angela Sirigu, France
14:45
16:15
State-of-the-Art Session: Upholding the Ethics of Transplantation: The Global View
N-117/118
369.1 Pakistan - the challenges and successes in transplantation
Adibul Hasan Rizvi, Pakistan
369.2 Establishment of a successful deceased donor program in Iran
Seyed Ali Malek-Hosseini, Iran
369.3 Achieving organ donor reform in China
Haibo Wang, P.R. China

Day 4 (2018-07-03)

14:45
16:15
State-of-the-Art Session: Outcome Driven Liver Transplantation
N-101
460.1 In depth cardiac Pre-It investigation: A necessity to improve outcome?
Samuel A Irefin, United States
460.2 Sarcopenia and denutrition: How to tackle these major determinants of outcome
Toshimi Kaido, Japan
460.3 Pre-L-T Antiviral Treatment (HCV,HBV, and HIV): Improving outcomes with and /or without liver transplantation
Christian P. Strassburg, Germany
14:45
16:15
State-of-the-Art Session: Improving Outcomes with Common Post-Transplant Infections
N-102
461.1 Prevention and management of CMV: Current guidance
Camille Kotton, United States
461.2 Multi-drug resistant bacterial infections: Understanding epidemiology and management of challenging infections
Jose Maria Aguado, Spain
461.3 Infectious complications of thoracic transplantation: The challenge of ECMO, LVAD and thoracic transplantation
Silvia Vidal Campos, Brazil
14:45
16:15
State-of-the-Art Session: Identifying the "At Risk" Renal Graft
N-103
462.1 The impact of disease recurrence on graft outcome
Germaine Wong, Australia
462.2 The development of DSA - who is at risk and what is the outcome
Alexandre Loupy, France
462.3 Histological predictors of premature graft loss
Brian J. Nankivell, Australia
14:45
16:15
State-of-the-Art Session: Engineering Immune System for Transplantation
N-104
463.1 Trained immunity in transplantation
Jordi Ochando, Spain
463.2 Antigen specific tregs - what is required for translation to the clinic
Megan Levings, Canada
463.3 Modulation of macrophage subsets to promote transplant survival
Xian C. Li, United States
14:45
16:15
State-of-the-Art Session: Beta-Cell Replacement Therapy: Current Outcomes and Future Landscape
N-105
464.1 Islet transplantation alone vs. solitary pancreas transplantation: An outcome driven choice?
Peter G. Stock, United States
464.2 SPK transplantation vs. living donor kidney transplantation alone: An outcome driven choice?
Adam D Barlow, United Kingdom
464.3 Future landscape: Defining a successful outcome using stem cells as a source of insulin producing cells
Lorenzo Piemonti, Italy
14:45
16:15
State-of-the-Art Session: Delivering Co-stimulation Blockade to the Clinic
N-106
465.1 The role for inhibition of the CD40-CD154 pathway in coxtimulation blockade
Flavio Vincenti, United States
465.2 New uses of Belatacept in kidney transplantation
Oriol Bestard Matamoros, Spain
465.3 Selective Anti-CD28 blockade: Finally getting there?
Lionel Rostaing, France
14:45
16:15
State-of-the-Art Session: A Multidisciplinary Approach in the Fight Against Organ Trafficking and Human Trafficking for Organ Removal
N-107/108
466.1 The role of clinicians in preventing and combatting organ trafficking
Benita Padilla, Philippines
466.2 The role of prosecutors
Gilad Erlich, Israel
466.3 The role of multinational organisations
Marta López-Fraga, France
14:45
16:15
State-of-the-Art Session: Why Does Sex Matter in Transplantation?
N-111
467.1 Sex on the bench
Deborah J Clegg, United States
467.2 Recipient sex related factors impacting transplant outcome
Bethany Foster, Canada
467.3 Considering sex and gender in transplantation research and clinical care
Christine S. Falk, Germany
14:45
16:15
State-of-the-Art Session: Improving Transplant Outcomes: Assessing Transplant Candidates' Risk
N-115/116
468.1 Assessing transplant candidates' risk: Frailty
Mara Ann McAdams DeMarco, United States
468.2 Assessing transplant candidates' risk: nonadherence
Miriam Kaufman, Canada
468.3 Assessing transplant candidates' risk: Poor social support and health literacy
Fabienne Dobbels, Belgium
14:45
16:15
State-of-the-Art Session: Perioperative Management: The Missing Link
N-117/118
469.1 Bridging the failing recipient candidate in the ICU
Catherine Paugam-Burtz, France
469.2 Back from the brink: Management of sepsis in the transplant recipient
Karl K. Young, Hong Kong
469.3 Cardiac evaluation for abdominal organ transplant: Angiography for all or overrated?
James Findlay, United States

Day 5 (2018-07-04)

14:30
16:00
State-of-the-Art Session: Adult LDLT: Long Term Outcome Problems
N-101
560.1 Long term outcome of endovascular venous intragraft stents in LDLT
Yu-Fan Cheng, Taiwan
560.2 Quality of life and lap donor hepatectomy
Daniel Cherqui, France
560.3 Can the minimal invasive surgery using laparoscopic or robotic technique replace open surgery in living donor hepatectomy in near future?
Kyung-Suk Suh, Korea
14:30
16:00
State-of-the-Art Session: Personalized Immunosuppression in 2018: “Which Biomarkers in Solid Organ Transplantation Will Pay Off ?”
N-102
561.1 Biomarkers for acute rejection in clinic: Show time or no time?
Manikkam Suthanthiran, United States
561.2 Biomarkers for chronic allograft dysfunction: What mark are we aiming for?
Barbara Murphy, United States
561.3 CNI minimization: How to foretell a good versus bad outcome?
Josep M. Cruzado, Spain
14:30
16:00
State-of-the-Art Session: Can We Solve the Discrepancy Between Demand and Supply
N-103
562.1 Increased risk and hepatitis C positive organs donors for HCV positive and negative recipients
Jay Fishman, United States
562.2 The challenges of older donors and recipients
Stefan G. Tullius, United States
562.3 The strengths and weaknesses of KDRI
Ron Shapiro, United States
14:30
16:00
State-of-the-Art Session: Metabolism in Transplantation
N-104
563.1 Preventing allograft rejection by targeting immune metabolism
Jonathan Powell, United States
563.2 Nutrient regulation of immune responses
Ping-Chih Ho, Switzerland
563.3 Manipulating macrophage responses in transplantation
James A. Hutchinson, Germany
14:30
16:00
State-of-the-Art Session: Best Use of Available Organs
N-105
564.1 DCD organs - what does the evidence say about outcomes?
Eduardo Miñambres, Spain
564.2 DCD perfusion techniques and outcomes
Gabriel C Oniscu, United Kingdom
564.3 DCD lung donation and lung reconditioning
Gregory Snell, Australia
14:30
16:00
State-of-the-Art Session: Obesity and Bone Disease – 21st century challenges for Transplantation
N-106
565.1 Features of postoperative bone complications specific to transplanted organs
Meltem Zeytinoglu, United States
565.2 Mechanisms of osteoporosis after organ transplantation and treatment
Sara Jiménez, Spain
565.3 Indication of bariatric surgery
Timucin Taner, United States
14:30
16:00
State-of-the-Art Session: Clinical Xenotransplantation-How Close Are We?
N-107/108
566.1 Kidney transplantation
Alfred J. Tector III, United States
566.2 Islet transplantation
Wayne J. Hawthorne, Australia
566.3 Heart transplantation
Muhammad Mohiuddin, United States
14:30
16:00
State-of-the-Art Session: The What, Who, When, Where and Why of Global Transplant Registries
N-111
567.1 The collaborative transplant study
Caner Süsal, Germany
567.2 WHO Global Observatory managed by Organizacion Nacional de Trasplantes (ONT)
Beatriz Dominguez-Gil, Spain
567.3 The harmonisation of national registries to measure global outcomes
Stephen P. McDonald, Australia
14:30
16:00
State-of-the-Art Session: Joint TTS-AST-ASTS-ESOT: Advancing Transplant Therapeutics and Innovation
N-115/116
568.1 The Transplant Therapeutics Consortium: Update on progress and goals
Roslyn B. Mannon, United States
568.2 Solidifying endpoints in clinical trials: SONG Tx Initiative
Allison Tong, Australia
568.3 Challenges involved in developing new endpoints for clinical trials
Stefan Schneeberger, Austria
Maarten Naesens, Belgium
Panel discussions
,
14:30
16:00
State-of-the-Art Session: ECMO in Thoracic Transplantation
N-117/118
569.1 ECMO for heart and lung donors vs. ex vivo perfusion
Christopher Wigfield, United States
569.2 ECMO intra- and postop in heart & lung transplantation
Olivier OB Bastien, France
569.3 Managing ECMO complications
Simon Maltais, United States


© 2018 TTS2018